and waist circumference in relation to a group of healthy subjects. Disturbance of the menstrual cycle was present in 57% of women with PCOS. Disturbance of the menstrual cycle was more common in PCOS patients with elevated body weight in relation to PCOS patients with normal body weight. Progesterone values showed that in the PCOS group, 85% of anovulatory cycle in contrast to the control group, where 7 % of anovulatory cycle were recorded.
INTRODUCTION
In approximately 50-70% of all women with PCOS (Polycystic Ovarian Syndrome) may be found in lower or higher degree insulin resistance, while insensitivity to insulin cells very likely contributes hyperandrogenaemia which is responsible for the symptoms and signs of PCOS (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Insulin resistance, PCOS and prediabetes are linked (11) (12) (13) (14) (15) (16) . Despite that is sometimes uncertain and unexpected, early detection and timely treatment of insulin resistance of infertile women with PCOS can significantly reduce the incidence of prediabetes and the incidence and severity of diabetes, disorders of lipid metabolism, hypertension and cardiovascular diseases. Hyperinsulinemia not only trigger hyperandrogenaemia and infertility, but also stimulates the activity of plasminogen activator inhibitor-1 (PAI-1), and thus the atherogenic effects of PCOS. The newer approach to treating PCOS by use of drugs that enhance the effectiveness of insulin metabolism provides new opportunities in the treatment of PCOS syndrome, both for the purpose of fertility treatment and in the prevention of long-term adverse and harmful effects.
Prediabetes is a condition in which blood glucose levels are higher than normal but not high enough to establish the diagnosis of diabetes. This condition is sometimes called impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)-impaired fasting glucose, depending on the test used to diagnose. People with prediabetes have an increased risk of developing type 2 diabetes (1, 3, 5) .
Polycystic ovary syndrome is a multisystem reproductive-metabolic disorder characterized by oligo/anovulation, hyperandrogenism and polycystic ovarian appearance. It is often associated with obesity and insulin resistance.
The syndrome has been described in 1905 by Stein and Leventhal as a set of symptoms: amenorrhea, hirsutism and obesity which are associated with increased and polycystic ovaries (1) . The authors have already rightly questioned the central role of ovaries in the development of signs and symptoms, because the application of bilateral resection and reduction of ovarian vol-ume in treated women led to the regulation of the menstrual cycle (1) .
Prediabetes has great significance in the prognosis and treatment of PCOS. It is necessary to prevent and control the disease, which leads to diabetes and its many complications including most important cardiovascular diseases, by methods for improving the quality and life duration.
GOALS
• To determine prediabetes prevalence in women with polycystic ovaries; • Determine the influence of insulin resistance degree on prediabetes in women with PCOS; • Establish correlation between prediabetes and obesity in female population with PCOS.
MATERIAL AND METHODS
This research is retrospective-prospective, clinical, comparative and descriptive. The study included 60 women with PCOS, aged 20-40 years, with no acute or chronic diseases, divided into two groups: PCOS women with elevated body weight and PCOS women with normal body weight. The control group is consisted of 30 female subjects without PCOS, aged 20-40 years. The research will be conducted at the Clinic for Endocrinology and Diabetes and the department of diagnostic and outpatient clinics at KCU Sarajevo and in BKH Niedernbayern. Criteria for inclusion in the study are: females with PCOS, aged 20-40 years, females without PCOS, aged 20-40 years and in absence of acute and chronic diseases. Exclusion criteria are: females younger than 20 and older than 40 years, females with acute and chronic illnesses and females with hypertension. In all subjects the following will be performed: clinical evaluation, laboratory tests and ovarian echosonography.
In the statistical analysis are used standard methods of descriptive statistics. To test the statistical significance of differences among the samples parametric and nonparametric tests of significance will be used.
RESULTS
Subjects with PCOS had significantly higher values of body weight, BMI and waist circumference in relation to a group of healthy subjects. Disturbance of the menstrual cycle was present in 57% of women with PCOS. Disturbance of the menstrual cycle was more common in PCOS patients with elevated body weight in relation to PCOS patients with normal body weight. Progesterone values showed that in the PCOS group, 85% of anovulatory cycle in contrast to the control group, where 7 % of anovulatory cycle were recorded.
A total of 28% of women with PCOS and 3% of control subjects had a positive family history of diabetes. The presence of diabetes in the family was more common in PCOS patients with elevated body weight in PCOS patients compared to normal weight.
Hirsutism, seborrhea, acne and alopecia were more common in PCOS patients with elevated body weight in relation to PCOS patients with normal body weight.
Total cholesterol did not differ significantly between the group with PCOS and control group but found statistically significant differences in the group with PCOS among women with elevated and normal body weight (p=0.03). The analysis of HDL cholesterol did not show statistically significant difference between group with PCOS and control group nor in the group with PCOS among women with elevated and normal body weight. LDL cholesterol and triglyceride levels were statistically significantly different between the groups with PCOS and control groups (p=0.03), as well as between the group with PCOS patients with elevated and normal body weight (p=0.02).
Values of CRP were significantly different between the group with PCOS and control group (p=0.004), as well as between the group with PCOS patients with elevated and normal body weight (p = 0.002). Mean values of CRP in the group of patients with elevated body weight corresponding to the area of subclinical inflammation. The analysis of mean values of fasting glucose and glucose 2 hours after OGTT was not statistically significant different between group with PCOS and control group as in the group with PCOS among women with elevated and normal body weight (p> 0.05).
Analysis of glucose values during OGTT showed that IGT had 10% of women with PCOS, 3% of patients in the control group and 10% of PCOS patients with elevated body weight and 10% of PCOS women with normal body weight. IFG had 5% of women with PCOS, 3% of patients in the control group and 7% of PCOS patients with elevated body weight and 1 (3%) patients with normal body weight. Diabetes was confirmed in 3% of women with PCOS. There were no diabetics in the control group.
There were no diabetics in the control group. The group with PCOS had a total of 18% of patients with some of the glucose intolerance (prediabetes-15% and diabetes-3%), whereas in the control group there were 6% of subjects with prediabetes. In the group of PCOS with increased body weight were the most common disorders of glucose regulation. The emergence of prediabetes significantly correlated with obesity (p<0.05). By analyzing the values of basal insulin, insulin values 2 hours after OGTT and the HOMA-IR values were significantly different between groups with PCOS and control groups (p=0.01), as well as between the group of PCOS patients with elevated and normal weight (p=0.009). The emergence of prediabetes significantly correlated with insulin resistance, which confirms the influence of the degree of insulin resistance on the occurrence of prediabetes.
The analysis of mean values of TSH, PRL, FSH and estradiol showed no statistically significant difference between groups with PCOS and control groups as well as between the group with PCOS patients with elevated and normal body weight (p> 0.05). The analysis of mean values of LH and LH/ FSH ratio showed a statistically significant difference between group with PCOS and control group (p=0.01), as well as between the group with PCOS patients with elevated and normal body weight. The analysis of mean values of testosterone and SBG showed a statistically significant difference between group with PCOS and control group (p=0.04), whereas in the group with PCOS among women with elevated and normal body weight there was no statistically significant difference (p> 0.05). The analysis of mean values of DHEAS showed a statistically significant difference between group with PCOS and control group (p=0.03), as well as between the group of PCOS patients with elevated and normal body weight (p=0.04). The analysis of mean values of androstenedione was not statistically significantly different between group with PCOS and control group (p>0.05), whereas in the group with PCOS among women with elevated and normal body weight there was statistically significant difference (p=0.04). Ultrasonic polycystic ovaries were confirmed within 45% of women. So, prediabetes as the result of the Frequency of Prediabetes in Women with Polycystic Ovary Syndrome degree of insulin resistance was positively correlated with obesity and had higher frequency in women with PCOS.
DISCUSSION
Polycystic ovary syndrome is a very complex and heterogeneous syndrome characterized by oligo and/or anovulation, hyperandrogenism and/or hyperandrogenaemia and ultrasound findings of polycystic ovaries (1). Since one in five women of reproductive age suffers from this syndrome, this disorder is considered the most common endocrinopathy of women in this age group. It has been shown that women with PCOS have an increased risk of central fat accumulation, insulin resistance, type 2 diabetes, hyperlipidemia, and cardiovascular disease. Because of its high prevalence and the number of metabolic disorders this syndrome is considered an important socioeconomic issue. Pathophysiological mechanism that connects the symptoms of PCOS with metabolic risk is not entirely clear.
It is clear that multiple risk factors influence the development of prediabetes in women with PCOS, to multiply the effect of each other and that many times threatened those patients who are obese. The patients with prediabetes have elevated atherogenic parameters (elevated total cholesterol, elevated LDL cholesterol, decreased HDLcholesterol, and hyperinsulinemia), which, along with obesity, contributes to its relation to cardiovascular events.
As body weight the women with PCOS in this study had significantly higher values of body weight and BMI in relation to a group of healthy subjects. Overweight was 13 subjects in the group with PCOS. Risky obesity had 15 women in the group with PCOS and very risky obesity had one woman with PCOS. The values of waist circumference also varied and they were higher in women with PCOS than in the control group, p=0.01. By analyzing the values of waist circumference, depending on body weight, we found that the values of waist circumference over the group of women with PCOS with increased body weight compared to women with PCOS who had a normal body weight, p=0.003. Consequences of PCOS are felt throughout the life. It seems that children with PCOS have shown a higher incidence of intrauterine growth impairment, and during the first year of life rapid weight gain (catch up growth), which in turn creates the risk of insulin resistance and type 2 diabetes (3, 4) . It also seems that girls with PCOS have pubic hairiness early (before eight years of age) and early menarche (3, 5) . During adolescence and the reproductive age are more common irregular menstrual cycles, acne, infertility and endometrial cancer. Women with PCOS have an increased incidence of spontaneous abortion, gestational diabetes, hypertension and pre-eclampsia. Women with PCOS usually as a result of complications during pregnancy often give birth by caesarean section, have the greater incidence of preterm birth and higher perinatal mortality. In women with PCOS common are obesity, glucose intolerance, insulin resistance, dyslipidemia and diabetes type 2. More frequent is abnormal vascular and endothelial function which together with the previously mentioned factors affecting increased risk for cardiovascular disease in women with PCOS. Women with PCOS often have sleep apnea, fatty degeneration of the liver and depression.
The analysis of the mean values of testosterone and SBG in our study, a statistically significant difference between the group with PCOS and control group (p=0.04) is noticed, whereas in the group with PCOS between patients with elevated and normal weight there was no statistically significant difference (p>0.05). The analysis of mean values of DHEAS, a statistically significant difference between the group with PCOS and control group is found (p=0.03), as well as in the group with PCOS between patients with elevated and normal weight (p=0.04). The analysis of mean values of androstenedione was not statistically significant different between the group with PCOS and control group (p>0.05), while in the group with PCOS between patients with increased and normal weight there was a statistically significant difference (p=0.04). Central fat accumulation, insulin resistance and compensatory hyperinsulinemia with metabolic profile similar to metabolic syndrome are common abnormalities in women with PCOS. Although these parameters are not a criterion for the diagnosis of PCOS they can exacerbate endocrine manifestations of hyperandrogenism and ovulatory dysfunction. Menstrual disorders in our study were present in 57% of patients with PCOS. Disruption of the menstrual cycle was more common in PCOS patients with elevated body weight in relation to PCOS women with normal body weight. Progesterone values showed that in the PCOS group was 85% of anovulatory cycles as opposed to the control group where it was recorded 7% anovulatory cycles. Hirsutism, seborrhea, acne and alopecia were more common in PCOS patients with elevated body weight in relation to PCOS women with normal body weight. Analysis of glucose values during OGTT showed that IGT had 10% of women with PCOS, 3% of patients in the control group and 10% of PCOS patients with elevated body weight and 10% of PCOS women with normal body weight. IFG had 5% of women with PCOS, 3% of patients in the control group and 7% of PCOS patients with elevated body weight and 1 (3%) patients with normal body weight. Diabetes was confirmed in 3% of women with PCOS. There were no diabetics in the control group. Studies have shown that 7-15% of women with PCOS already have type 2 diabetes, up to 30 years of age, which is significantly higher incidence of 1.4% which is found in women without PCOS. Women with PCOS have a higher prevalence of hypertension, dyslipidemia, endothelial dysfunction and cardiovascular diseases (3, 6) .
In the group with PCOS there were 18% of the patients with some of the glucose disorders (prediabetes 15%and diabetes 3%), while in the control group there were 6% of the subjects with abnormal glucose-prediabetes. In the group of PCOS patients with elevated body weight were the most common disorders of glycemic control. We analyzed the occurrence of prediabetes association with obesity in women with PCOS, and we get the value of the correlation coefficient r=0.72, which was statistically significant (p<0.05). Dyslipidemia can be found in 70% of women with PCOS (1) . The values of total cholesterol in our study did not differ significantly between the groups with PCOS and control group but we found a statistically significant difference in the group with PCOS between patients with increased and normal weight (p=0.03). The analysis of HDL cholesterol did not show any statistically significant difference between the group with PCOS and control group as well as in the group with PCOS between patients with increased and normal weight. LDL cholesterol and triglyceride levels were statistically significantly different between the group with PCOS and control group (p=0.03), as well as in the group with PCOS between patients with increased and normal weight (p=0.02).
Numerous studies suggest an increased incidence of atherosclerosis in relation to the general population (1) . The analysis of CRP in the study demonstrated a statistically significant difference between the group with PCOS and control group (p=0.004), as well as in the group with PCOS between patients with increased and normal weight (p=0.002). Mean values in a group of patients with elevated body weight correspond to the subclinical inflammation.
There seems to be an increased risk of early cardiovascular disease in women with PCOS. Increased incidence of cardiovascular disease was also found in postmenopausal women who had previously suffered from PCOS (2, 4) . Metabolic syndrome will develop in 46% of women with PCOS. The incidence of metabolic syndrome in women over the age of 40 years is equal to the frequency of metabolic syndrome in women 70 years of age without PCOS, making this syndrome represents a significant public health and socio-economic problem.
Given that central fat accumulation, insulin resistance and increased risk of metabolic syndrome are common companions of PCOS in this study are compared lipids, insulin and markers of subclinical inflammation in women with PCOS with values of healthy subjects. The analysis of the mean values of basal insulin, insulin values 2 hours after OGTT and HOMA-IR values in the study, a statistically significant difference between the group with PCOS and control group is determined (p=0.01), as well as in the group with PCOS among women with increased and normal weight (p=0.009).
CONCLUSION
The emergence of prediabetes is significantly correlated with insulin resistance as confirms the impact of the insulin resistance degree to the emergence of prediabetes. Knowledge about the existence of high prediabetes prevalence in women with PCOS will help in the decision on mandatory screening, more prompt diagnosis and treatment, which could prevent or delay the onset of the formation of clinically manifested diabetes. Prediabetes can be a reversible process with improved metabolic control and the use of metformin in prediabetes in women with PCOS may prevent or slow down the onset of type 2 diabetes. Table 6 . Analysis of hormonal parameters in PCOS and control group *Student's T-test for independent samples
